Supplementary Files
Keywords
Metabolic syndrome
Risk factors
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To review the scientific literature on Supraventricular and Ventricular Arrhythmias in patients with Metabolic Syndrome (MS). Methods: Integrative literature review, with searches on Pubmed, Google Scholar, Lilacs, of articles from the last 10 years. The descriptors used were ¨Metabolic Syndrome¨ AND ¨Arrythmia¨. Inclusion Criteria: (1) be performed in humans; (2) sample people over 18 years of age; (3) use the parameters established by the WHO, NCEP-ATPIII or IDF as criteria for MS; (4) having a control group; (5) the study population does not have other chronic comorbidities such as multiple sclerosis, chronic kidney disease, heart problems and others; (6) to correlate cardiac arrhythmia parameters with MS between MS- and MS+ patients. Results: Eight articles met the inclusion criteria. All articles worked with people drawn from the general population. Both sexes were addressed in the works. Atrial Fibrillation (AF) was the predominant arrhythmia. The most relevant factors when evaluated individually were SAH and Abdominal Obesity. Final Considerations: The more severe the patient's MS condition, the more severe the arrhythmia. Therefore, it is evident the importance of maintaining a healthy lifestyle to avoid the development of risk factors that trigger the Metabolic Syndrome.
References
AFZAL MR, et al. Hypertension and Arrhythmias. Heart failure clinics, 2019; 15(4): 543–550.
AHN HJ, et al. Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study. Cardiovascular diabetology, 2021; 20(1): 20.
CHRISTENSEN RH, et al. Effect of Aerobic and Resistance Exercise on Cardiac Adipose Tissues. JAMA Cardiology, 2019; 4(8): 778.
DECKER JJ, et al. Metabolic Syndrome and Risk of Ischemic Stroke in Atrial Fibrillation: ARIC Study. Stroke, 2019; 50(11): 3045–3050.
DELHEY L, et al. The association of metabolic syndrome and QRS|T angle in US adults (NHANES III). Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2020; 25(1): 1-8.
FARAMAWI MF, et al. Metabolic syndrome and P-wave duration in the American population. Annals of epidemiology, 2020; 46: 5–11.
FUMAGALLI C, et al. Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020; 5(1): 65.
GOONASEKARA, CL, et al. Cholesterol and cardiac arrhythmias. Expert review of cardiovascular therapy, 2010; 8(7): 965–979.
HOHL M, et al. Concomitant Obesity and Metabolic Syndrome Add to the Atrial Arrhythmogenic Phenotype in Male Hypertensive Rats. Journal of the American Heart Association, 2017; 6(9): 17.
KÄRÄJÄMÄKI AJ, et al. Long-term metabolic fate and mortality in obesity without metabolic syndrome. Annals of medicine, 2022; 54(1): 1432–1443.
KURT M, et al. The relationship between atrial electromechanical delay and P-wave dispersion with the presence and severity of metabolic syndrome. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2012; 40(8): 663–670.
LAVIE CJ, et al. Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise. Journal of the American College of Cardiology, 2017; 70(16): 2022–2035.
LEE HC, et al. Very-Low-Density Lipoprotein of Metabolic Syndrome Modulates Gap Junctions and Slows Cardiac Conduction. Scientific reports, 2017; 7(1): 1-12.
LEE SY, et al. Association Between Change in Metabolic Syndrome Status and Risk of Incident Atrial Fibrillation: A Nationwide Population-Based Study. Journal of the American Heart Association, 2021; 10(16): 1-23.
MAGNANI JW, et al. P wave indices, obesity, and the metabolic syndrome: the atherosclerosis risk in communities study. Obesity (Silver Spring, Md.), 2012; 20(3): 666–672.
NYSTRÖM PK, et al. Obesity, Metabolic Syndrome and Risk of Atrial Fibrillation: A Swedish, Prospective Cohort Study. (N. Maeda, Org.)PLOS ONE, 2015; 10(5): 111-127.
ORNELAS-LOREDO A, et al. Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs. JAMA Cardiology, 2020; 5(1): 57.
PAPADOPOULOS CH, et al. Echocardiography and cardiac arrhythmias. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, [S.d.]; 59(3): 140–149.
PARK B, et al. Metabolic syndrome and its components as risk factors for prolonged corrected QT interval in apparently healthy Korean men and women. Journal of clinical lipidology, 2018; 12(5): 1298–1304.
ROCHLANI Y, et al. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic advances in cardiovascular disease, 2017; 11(8): 215–225.
SAFRANOW K, et al. Inflammation markers are associated with metabolic syndrome and ventricular arrhythmia in patients with coronary artery disease. Postepy higieny i medycyny doswiadczalnej (Online), 2016; 70: 56–66.
THOMSEN M, et al. Myocardial Infarction and Ischemic Heart Disease in Overweight and Obesity With and Without Metabolic Syndrome. JAMA Internal Medicine, 2014; 174(1): 15.
WANG TJ, et al. Obesity and the Risk of New-Onset Atrial Fibrillation. JAMA, 2004; 292(20): 2471.